Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Eyedea Bio LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, creating separate examination tracks.
REYNOLDS, FRED H is the busiest examiner, with 1 pending matter. Portfolio coordination can preserve consistent technical positions, while each response should address its own examination record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566629 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | FAY, ZOHREH ALEMZADEH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566627 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566629 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18566627 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | REYNOLDS, FRED H | 1658 | §103§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEyedea Bio LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Eyedea Bio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
